Manufacturing Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunities Pharmaceutical TechnologyManufacturing deals saw an unusual burst of recent activity, with a spike in the number of CDMOs acquiring facilities from pharma companies.Read full story pharminent May 12, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology Manufacturing deals saw an unusual burst of recent activity, with a spike in the number of CDMOs acquiring facilities from pharma companies. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trialNext: FDA weighs drug repurposing pathway for underserved diseases Related Stories Manufacturing FDA Warning Letter Hits Sanofi’s Genzyme Ireland Site pharminent July 8, 2026 Manufacturing Tanabe pens deal to sell plants to Towa in post-buyout pivot pharminent July 8, 2026 Manufacturing FDA Selects Seven for PreCheck Pilot to Advance Drug Manufacturing pharminent July 1, 2026
